source
- Belgian startup Armed Cell Therapeutics acquires Galapagos-derived CAR-T assets for €8 million upfrontArmed Cell Therapeutics, a new Belgian biotech chaired by former Galapagos CEO Paul Stoffels, has taken ownership of several cell therapy programs previously held by Lakefront Biotherapeutics. The…
- Melanoma patient shares hope after receiving Merck-Moderna mRNA cancer vaccine in trialA schoolteacher diagnosed with melanoma in 2019 participated in a late‑stage trial testing an mRNA cancer vaccine developed by Merck and Moderna. The trial added the vaccine to standard immunothera…